ATXN3

Across TCGA pan-cancer cohorts, ATXN3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ATXN3 data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ATXN3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ATXN3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LSCC, PDAC, and HNSC are the cancer types where ATXN3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	All	0.930	0.598	<.001	25	view →
PDAC	DFS	Median	III,IV	0.592	0.170	<.001	24	view →
HNSC	DFS	Tertile	All	1.000	0.895	.005	14	view →
CCRCC	DFS	Quartile	III,IV	0.892	0.298	.001	9	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ATXN3–LSCC (OS)

Open the LSCC breakdown →